A new study conducted by Henry Ford Health System in Southeast Michigan revealed good news regarding the use of hydroxychloroquine in patients infected with the CCP (Chinese Communist Party) Virus, also known as COVID-19. The research indicated that hydroxychloroquine treatment significantly reduces the death rate in sick patients hospitalized with the virus and without heart-related side effects. The study was published in the International Journal of Infectious Diseases on Thursday, July 2.
The research was based on a large-scale multihospital retrospective analysis of 2,541 patients. The results showed that the mortality of patients treated with hydroxychloroquine was 13.5% compared to 26.4% who received no treatment at all, meaning “a 66% risk ratio reduction.” The combination of treatment with azithromycin was also analyzed and the reduction in the risk of hospital mortality in this case was “71% compared to none of the treatments.”
Hydroxychloroquine is a drug commonly used for the treatment and prevention of malaria and also in some autoimmune diseases. Its use in the treatment of patients infected with the CCP Virus, however, has caused great controversy in the scientific community.
A few weeks before the study was published, the U.S. Food and Drug Administration (FDA) had disallowed the emergency use of hydroxychloroquine as a treatment for hospitalized patients infected with the CCP Virus, discrediting its effectiveness in eliminating the virus. On July 1, the FDA also published a review of articles on the safety of hydroxychloroquine use, warning of “serious heart problems” among other harmful effects.
However, researchers at the Henry Ford Health System indicated that early treatment with this drug may be the key. “What we think was important in ours … is that patients were treated early. For hydroxychloroquine to have a benefit, it needs to begin before the patients begin to suffer some of the severe immune reactions that patients can have with COVID,” said Dr. Marcus Zervus, director of the system’s infectious disease division.
Researchers also indicated, “Prospective trials are needed” for further review, but concluded, “In this multihospital assessment, when controlling for COVID-19 risk factors, treatment with hydroxychloroquine alone and in combination with azithromycin was associated with reduction in COVID-19 associated mortality.”
These new results bring good news for the campaign of President Trump, who has been heavily criticized for encouraging the use of hydroxychloroquine in the treatment of the CCP Virus.
Already in March of this year at the White House the president announced, “Now, a drug called chloroquine, and some people would add, hydroxychloroquine, therefore chloroquine or hydroxychloroquine … [has shown] very encouraging initial results, very encouraging.”
The wave of criticism in the media and social networks was immediate, accusing President Trump of spreading “false hope,” among other statements.“Trump’s most dangerous flim-flam: False hope and quack advice (Salon),” “
Coronavirus treatment: Dr. Donald Trump peddles snake oil and false hope“ (USA Today),
“Trump is spreading false hope for a virus cure — and that’s not the only damage.” (Washington Post), are some examples.
In the media frenzy over this issue, recent campaign statements for President Trump point out, “The new study from the Henry Ford Health System should be a clear message to the media and the Democrats: stop the bizarre attempts to discredit hydroxychloroquine to satisfy your own anti-Trump agenda. It may be costing lives.”
While there are still disagreements over the use of hydroxychloroquine in treating the virus, these new findings open up the game and could put this drug at the center of new research.